About GSK
GSK is a publicly listed company based in Brentford (United Kingdom) founded in 1715, and was acquired by Unilever in December 2018. Developer of pharmaceuticals and vaccines for various therapeutic areas. The company has 91,864 employees. GSK has completed 23 acquisitions, including 35Pharma, Affinivax and Aiolos Bio. Its chief executive, as recorded, is Dame Emma Walmsley. Its website gsk.com draws about 1.3 million monthly visits. Its Indian entity Glaxosmithkline Pharmaceuticals Limited reported revenue of βΉ3,988 Cr. Its focus areas include Diversified Pharmaceuticals.
Company details
Founded in 1715, GSK operates in the pharmaceutical sector, with a focus on research, development, clinical trials, and commercialization of medicines and vaccines. Treatments are provided for respiratory, immunology, inflammatory, oncology, HIV, and infectious diseases. Global access to products is emphasized, alongside sustainable practices, from its base in Brentford, United Kingdom.
- Market Cap₹44,693 Cr
GLAXO · NSE
- Share Price₹2,631.90
-0.24% today
- Revenue₹3,822 Cr
FY 2025-26 · +1.9% YoY
- EBITDA₹1,309 Cr
Margin 34.3%
- Net Profit₹962 Cr
FY 2025-26 · +10.1% YoY
- P/E (TTM)39.6x
P/B 23.9x
- ROE49.1%
ROCE 59.0%
- Debt / Equity0.01
Interest cover 0.2x
- Latest Funding Round$415.25K (USD), Grant
Dec 2023
- InvestorsUnilever
& 9 more
- Employee Count91,864
- Investments & Acquisitions35Pharma
& 22 more
- Acquired byUnilever
(Dec 2018)
Associated legal entities of GSK
GSK operates through Glaxosmithkline Pharmaceuticals Limited, a listed company (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2026) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Glaxosmithkline Pharmaceuticals Limited Listed CIN L24239MH1924PLC001151 | Active | 13 Nov 1924 | Mumbai, Maharashtra | ₹3,988 Cr | 505 | 10 | View details |
Apps and channels of GSK
its YouTube channel ViiV Healthcare has 133 subscribers and 30 videos.
Videos from GSK
The most watched videos on GSK's YouTube channel, ViiV Healthcare (133 subscribers). Click a video to play it here.
More on ViiV Healthcare.
Funding Insights of GSK
- Total Rounds 29
- Last Round Grant β $415,246
- First Round $393,750
(Jul 2008)
- Investors Count 9
Latest 10 of 29 funding rounds of GSK with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2023 | $415,246 | Grant | β | β | |
| Nov 2023 | $433,387 | Grant | β | β | |
| Nov 2023 | $909,024 | Grant | β | β | |
| Apr 2023 | $106,185 | Grant | β | β | |
| Apr 2023 | $126,591 | Grant | β | β | |
| Jun 2022 | $247,384 | Grant | β | β | |
| Sep 2021 | Post-IPO | β | β | ||
| Apr 2021 | Post-IPO | β | β | ||
| Mar 2021 | $8.2M | Grant | β | β | |
| Aug 2020 | Grant | β | β |
10 investors in total: 10 institutional.
Investors in GSK
GSK has secured backing from 10 investors, including institutional investors. Prominent investors backing the company include Unilever, Elliott Management and Scottish Enterprise.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| economie.gouv.fr | ||||
| mhsr.sk | ||||
Activist investing in undervalued European public equities through engagement. | 2019 | bluebellcp.com | London, United Kingdom | |
Antibiotics, vaccines, and diagnostics against drug-resistant bacteria are developed. | 2016 | carb-x.org | Boston, United States | |
Government entity focused on information and services | 2000 | usa.gov | United States | |
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
Business development and leadership training programs are offered to companies. | 1991 | scottish-enterprise.com | Glasgow, United Kingdom | |
Multiple sectors are invested in by the hedge fund. | 1977 | elliottmgmt.com | New York, United States | |
Administers health care and support for military personnel and operations. | health.mil | Falls Church, United States | ||
A global consumer goods business with diverse product offerings. | 1872 | unilever.com | London, United Kingdom |
Investor details for GSK
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Glaxosmithkline Pharmaceuticals Limited (GSK)
Glaxosmithkline Pharmaceuticals Limited is the primary company behind GSK. The board of Glaxosmithkline Pharmaceuticals Limited currently have 8 directors; the longest-serving is Subesh Ronald Williams, appointed in 2017. 32 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Subesh Ronald Williams DIN 07786724 | Director | 07 Apr 2017 | 9 yrs 7 mo | Glaxosmithkline Pharmaceuticals Limited |
| Renu Sud Karnad DIN 00008064 | Director | 01 Apr 2019 | 7 yrs 7 mo | Glaxosmithkline Pharmaceuticals Limited |
| Sunita Maheshwari DIN 01641411 | Director | 18 May 2020 | 6 yrs 6 mo | Glaxosmithkline Pharmaceuticals Limited |
| Manu Anand DIN 00396716 | Director | 16 May 2022 | 4 yrs 6 mo | Glaxosmithkline Pharmaceuticals Limited |
| Bhushan Arun Akshikar DIN 09112346 | Managing Director | 01 Dec 2022 | 3 yrs 11 mo | Glaxosmithkline Pharmaceuticals Limited |
| Somasundaram Palamadairamaswamy DIN 00356363 | Director | 26 Mar 2025 | 1 yr 7 mo | Glaxosmithkline Pharmaceuticals Limited |
| Anup Wadhawan DIN 03565167 | Director | 26 Mar 2025 | 1 yr 7 mo | Glaxosmithkline Pharmaceuticals Limited |
| Ronojit Biswas DIN 07684843 | Whole-Time Director | 01 Apr 2026 | 7 mo | Glaxosmithkline Pharmaceuticals Limited |
People of GSK
963 people are tracked at GSK (579 in leadership, 9 in board & advisors, 375 in team); the tracked headcount is 91,864.
| Name | Role | Group |
|---|---|---|
Dame Emma Walmsley | CEO | Leadership |
Julie Brown | CFO | Leadership |
Enoch Acquah | Production Value Stream Director | Leadership |
Rosirene Paczkowski | Director | Leadership |
Avijit Ray | Director | Leadership |
John Hong | Medicine Supply Chain Leader (director) | Leadership |
Angela Avila | Finance Director | Leadership |
Sarit Cohen-Rabbie | Clinical Development Director, Immunology | Leadership |
Renata Scofield | Global Senior Director, Environmental Stewardship | Leadership |
David Redfern | President, Corporate Development | Leadership |
Jiaying Ji | Head Of China Talent Acquisition | Leadership |
Sean Evans | Director, Strategic Alliances | Leadership |
Sergio Serrano Caballero | Digital Business Partner | Leadership |
Heidi Feldser | Scientific Director | Leadership |
Kyle Robinson | Associate Director External Operations | Leadership |
Christophe Lambert | Head Of Viral Computational Genomics | Leadership |
Rajesh Gurumurthy | Director Strategic Procurement (senior Principal Product Owner) Global Products & Technology | Leadership |
Victoria Sanchez Zini | Director R&d Strategy - RD Strategy & Portfolio Management / Office Of The CSO | Leadership |
Cristelle Noirhomme | Head Of Belgium Corporate Government Affairs | Leadership |
Yogitaa Gahlot Saha | Director - Finance | Leadership |
943 more people are available in the full profile.
Complete people profiles for GSK
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of GSK
GSK is a publicly listed company on the LSE with ticker symbol GSK in UK, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date16 Jun 2003
- Listed onNSE: GSKCONS
- Listed entityGSK plc
- Exchange sectorHealth technology
- ISINGB00BN7SWP63
- Share price1,759.00 GBX (+0.34% on the day) · 2026-10-14
- Market capitalisation70,243,247,725.00 GBX
- Price to earnings14.9
- EPS (diluted, trailing year)1.18 GBX
- Dividend yield3.88%
- Volume (last session)624,599
Financials of GSK
Exchange-reported figures of Glaxosmithkline Pharmaceuticals Limited, the listed company behind GSK (NSE: GLAXO).
Financial Highlights
FY 2025-26 Β· ConsolidatedRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 3,822 | 3,749 | 3,454 | 3,252 | 3,278 | 2,926 | 3,224 |
| Revenue growth | +1.9% | +8.6% | +6.2% | -0.8% | +12.1% | -9.3% | - |
| EBITDA | 1,309 | 1,177 | 745 | 793 | 740 | 389 | (231) |
| EBITDA margin | +34.3% | +31.4% | +21.6% | +24.4% | +22.6% | +13.3% | -7.2% |
| Profit before tax | 1,406 | 1,260 | 816 | 839 | 2,093 | 525 | 306 |
| Net profit | 962 | 874 | 657 | 590 | 1,684 | 476 | 144 |
| Net profit margin | +25.2% | +23.3% | +19.0% | +18.1% | +51.4% | +16.3% | +4.5% |
| EPS (βΉ) | 61.15 | 54.76 | 34.83 | 36.05 | 100.04 | 21.14 | 5.50 |
| Balance sheet | |||||||
| Total assets | 2,561 | 2,210 | 2,044 | 2,012 | 2,947 | 1,774 | 2,111 |
| Net worth | 2,267 | 1,951 | 1,778 | 1,741 | 2,663 | 1,478 | 1,821 |
| Total debt | 33.27 | 9.95 | 18.67 | 15.54 | 20.08 | 34.63 | 0.18 |
| Cash & bank | 1,391 | 1,404 | 1,063 | 1,156 | 2,485 | 1,158 | 1,083 |
| Net working capital | 452 | 394 | 472 | 662 | 1,656 | 862 | 751 |
| Cash flow | |||||||
| Cash from operations | 903 | 1,290 | 582 | 484 | 811 | 578 | 490 |
| Cash from investing | 397 | (45.80) | 8.71 | 808 | (406) | 418 | (56.84) |
| Cash from financing | (737) | (769) | (562) | (1,543) | (524) | (696) | (428) |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1,184 | 938 | 995 | 1,041 | 980 | 805 | 974 | 949 |
| Revenue growth (YoY) | +20.8% | +16.6% | +2.2% | +9.7% | -3.1% | -1.2% | - | - |
| Other income | 72.78 | 43.76 | 35.95 | 50.10 | 36.21 | 43.72 | 40.68 | 35.07 |
| EBITDA | 402 | 296 | 351 | 371 | 336 | 251 | 333 | 292 |
| EBITDA margin | +34.0% | +31.5% | +35.3% | +35.7% | +34.3% | +31.2% | +34.2% | +30.7% |
| Depreciation | 15.02 | 15.84 | 13.17 | 20.32 | 17.43 | 15.52 | 14.72 | 18.80 |
| Interest | 0.49 | 0.97 | 0.61 | 1.19 | 0.51 | 0.42 | 0.58 | 0.09 |
| Profit before tax | 459 | 322 | 373 | 400 | 354 | 279 | 359 | 308 |
| Tax | 123 | 85.27 | 95.24 | 104 | 96.51 | 73.97 | 95.70 | 78.22 |
| Net profit | 336 | 237 | 278 | 296 | 257 | 205 | 263 | 230 |
| EPS (βΉ) | 19.83 | 14.00 | 16.40 | 17.45 | 15.02 | 12.10 | 15.52 | 13.57 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 3,790 | 3,723 | 3,407 | 3,216 | 3,218 | 2,920 | 3,225 |
| Revenue growth | +1.8% | +9.3% | +5.9% | -0.0% | +10.2% | -9.4% | - |
| EBITDA | 1,300 | 1,169 | 737 | 788 | 734 | 389 | (213) |
| EBITDA margin | +34.3% | +31.4% | +21.6% | +24.5% | +22.8% | +13.3% | -6.6% |
| Profit before tax | 1,376 | 1,248 | 809 | 835 | 2,087 | 524 | 322 |
| Net profit | 908 | 827 | 651 | 587 | 1,679 | 475 | 197 |
| Net profit margin | +24.0% | +22.2% | +19.1% | +18.2% | +52.2% | +16.3% | +6.1% |
| EPS (βΉ) | 59.73 | 54.25 | 34.51 | 35.88 | 99.79 | 21.11 | 6.50 |
| Balance sheet | |||||||
| Total assets | 2,534 | 2,208 | 2,049 | 2,023 | 2,961 | 1,792 | 2,130 |
| Net worth | 2,241 | 1,949 | 1,784 | 1,753 | 2,678 | 1,497 | 1,840 |
| Total debt | 33.27 | 9.95 | 18.67 | 15.54 | 20.08 | 34.63 | 0.18 |
| Cash & bank | 1,355 | 1,401 | 1,061 | 1,151 | 2,479 | 1,158 | 1,066 |
| Net working capital | 411 | 372 | 454 | 644 | 1,643 | 866 | 755 |
| Cash flow | |||||||
| Cash from operations | 881 | 1,280 | 579 | 488 | 820 | 595 | 491 |
| Cash from investing | 385 | (36.53) | 14.97 | 805 | (420) | 408 | (63.10) |
| Cash from financing | (737) | (769) | (562) | (1,544) | (524) | (696) | (428) |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1,180 | 924 | 989 | 1,023 | 974 | 805 | 966 | 946 |
| Revenue growth (YoY) | +21.2% | +14.9% | +2.4% | +8.1% | -2.6% | -0.8% | - | - |
| Other income | 72.77 | 61.63 | 35.71 | 31.82 | 33.91 | 43.76 | 39.46 | 35.06 |
| Total expenses | 780 | 631 | 642 | 655 | 639 | 554 | 635 | 656 |
| EBITDA | 400 | 293 | 347 | 368 | 335 | 251 | 331 | 290 |
| EBITDA margin | +33.9% | +31.7% | +35.1% | +35.9% | +34.4% | +31.2% | +34.2% | +30.7% |
| Depreciation | 15.02 | 15.84 | 13.17 | 20.32 | 17.43 | 15.52 | 14.72 | 18.80 |
| Interest | 0.49 | 0.97 | 0.61 | 1.19 | 0.51 | 0.42 | 0.58 | 0.09 |
| Profit before tax | 458 | 338 | 369 | 378 | 351 | 279 | 355 | 306 |
| Tax | 123 | 84.65 | 94.18 | 101 | 95.65 | 73.87 | 94.76 | 77.77 |
Financial Statements
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1,184 | 938 | 995 | 1,041 | 980 | 805 | 974 | 949 |
| Revenue growth (YoY) | +20.8% | +16.6% | +2.2% | +9.7% | -3.1% | -1.2% | - | - |
| Other income | 72.78 | 43.76 | 35.95 | 50.10 | 36.21 | 43.72 | 40.68 | 35.07 |
| EBITDA | 402 | 296 | 351 | 371 | 336 | 251 | 333 | 292 |
| EBITDA margin | +34.0% | +31.5% | +35.3% | +35.7% | +34.3% | +31.2% | +34.2% | +30.7% |
| Depreciation | 15.02 | 15.84 | 13.17 | 20.32 | 17.43 | 15.52 | 14.72 | 18.80 |
| Interest | 0.49 | 0.97 | 0.61 | 1.19 | 0.51 | 0.42 | 0.58 | 0.09 |
| Profit before tax | 459 | 322 | 373 | 400 | 354 | 279 | 359 | 308 |
| Tax | 123 | 85.27 | 95.24 | 104 | 96.51 | 73.97 | 95.70 | 78.22 |
| Net profit | 336 | 237 | 278 | 296 | 257 | 205 | 263 | 230 |
| EPS (βΉ) | 19.83 | 14.00 | 16.40 | 17.45 | 15.02 | 12.10 | 15.52 | 13.57 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 3,822 | 3,749 | 3,454 | 3,252 | 3,278 | 2,926 | 3,224 |
| Revenue growth | +1.9% | +8.6% | +6.2% | -0.8% | +12.1% | -9.3% | - |
| Other income | 166 | 151 | 142 | 114 | 1,423 | 218 | 626 |
| Total expenses | 2,512 | 2,572 | 2,708 | 2,459 | 2,538 | 2,537 | 3,455 |
| Employee cost | 607 | 580 | 624 | 595 | 610 | 616 | 629 |
| EBITDA | 1,309 | 1,177 | 745 | 793 | 740 | 389 | (231) |
| EBITDA margin | +34.3% | +31.4% | +21.6% | +24.4% | +22.6% | +13.3% | -7.2% |
| Depreciation | 66.44 | 66.79 | 69.68 | 65.77 | 68.19 | 78.60 | 82.68 |
| Interest | 2.73 | 1.31 | 1.80 | 1.81 | 2.00 | 3.53 | 6.34 |
| Profit before tax | 1,406 | 1,260 | 816 | 839 | 2,093 | 525 | 306 |
| Tax | 370 | 332 | 226 | 229 | 398 | 167 | 213 |
| Net profit | 962 | 874 | 657 | 590 | 1,684 | 476 | 144 |
| Net profit margin | +25.2% | +23.3% | +19.0% | +18.1% | +51.4% | +16.3% | +4.5% |
| EPS (βΉ) | 61.15 | 54.76 | 34.83 | 36.05 | 100.04 | 21.14 | 5.50 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 169 | 169 | 169 | 169 | 169 | 169 | 169 |
| Reserves & surplus | 2,098 | 1,782 | 1,608 | 1,572 | 2,494 | 1,309 | 1,651 |
| Shareholders' funds (net worth) | 2,267 | 1,951 | 1,778 | 1,741 | 2,663 | 1,478 | 1,821 |
| Minority interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Secured loans | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Unsecured loans | 33.27 | 9.95 | 18.67 | 15.54 | 20.08 | 34.63 | 0.18 |
| Total debt | 33.27 | 9.95 | 18.67 | 15.54 | 20.08 | 34.63 | 0.18 |
| Total liabilities | 2,561 | 2,210 | 2,044 | 2,012 | 2,947 | 1,774 | 2,111 |
| Assets | |||||||
| Gross block | 700 | 669 | 666 | 636 | 594 | 603 | 1,472 |
| Net block | 281 | 284 | 321 | 330 | 331 | 387 | 758 |
| Capital work in progress | 32.93 | 14.32 | 13.93 | 20.31 | 30.50 | 13.21 | 120 |
| Investments | 1,392 | 1,118 | 813 | 518 | 366 | 0.00 | 0.00 |
| Inventories | 458 | 482 | 525 | 460 | 535 | 547 | 483 |
| Sundry debtors | 273 | 293 | 222 | 192 | 205 | 216 | 99.80 |
| Cash & bank balances | 1,391 | 1,404 | 1,063 | 1,156 | 2,485 | 1,158 | 1,083 |
| Loans & advances | 93.55 | 114 | 175 | 168 | 118 | 282 | 109 |
| Total current assets | 2,215 | 2,292 | 1,985 | 1,976 | 3,342 | 2,203 | 1,775 |
| Total current liabilities | 1,763 | 1,898 | 1,513 | 1,314 | 1,686 | 1,340 | 1,024 |
| Net working capital | 452 | 394 | 472 | 662 | 1,656 | 862 | 751 |
| Total assets | 2,561 | 2,210 | 2,044 | 2,012 | 2,947 | 1,774 | 2,111 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 539 | 64.17 | 34.94 | 286 | 405 | 105 | 98.78 |
| Net cash from operating activities | 903 | 1,290 | 582 | 484 | 811 | 578 | 490 |
| Net cash from investing activities | 397 | (45.80) | 8.71 | 808 | (406) | 418 | (56.84) |
| Net cash from financing activities | (737) | (769) | (562) | (1,543) | (524) | (696) | (428) |
| Net change in cash | 563 | 475 | 29.23 | (251) | (119) | 300 | 6.03 |
| Closing cash | 1,391 | 1,404 | 1,063 | 1,156 | 2,485 | 1,158 | 1,083 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +1.9% | +8.6% | +6.2% | -0.8% | +12.1% | -9.3% | - |
| EBITDA growth | +11.2% | +58.0% | -6.0% | +7.1% | +90.4% | +268.3% | - |
| PBT growth | +11.6% | +54.4% | -2.8% | -59.9% | +298.8% | +71.7% | -55.2% |
| Net income growth | +10.1% | +33.1% | +11.4% | -65.0% | +253.7% | +231.1% | - |
| Revenue CAGR (3Y) | +5.5% | +4.6% | +5.7% | +0.3% | +1.6% | +0.6% | +3.5% |
| EBITDA CAGR (3Y) | +18.2% | +16.7% | +24.2% | - | +8.4% | -8.4% | - |
| Profitability & leverage | |||||||
| Net income margin | +27.1% | +24.7% | +17.1% | +18.8% | +51.7% | +12.2% | +2.9% |
| Return on capital employed | +59.1% | +59.3% | +45.0% | +33.9% | +32.6% | +32.4% | +28.5% |
| Return on net worth | +49.1% | +49.8% | +37.3% | +27.7% | +81.3% | +28.9% | +7.3% |
| Debt / equity | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 |
| Long-term debt / equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.00 |
| Interest cover | 0.22 | 0.12 | 0.27 | 0.25 | 0.30 | 1.14 | -2.02 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 5.58 | 5.62 | 5.31 | 5.29 | 5.48 | 2.82 | 3.17 |
| Inventory turnover | 8.14 | 7.45 | 7.01 | 6.54 | 6.06 | 5.68 | 6.65 |
| Debtors turnover | 13.51 | 14.57 | 16.67 | 16.36 | 15.58 | 18.55 | 29.27 |
| EPS (βΉ) | 61.15 | 54.76 | 34.83 | 36.05 | 100.04 | 21.14 | 5.50 |
| Dividend per share (βΉ) | 57.00 | 54.00 | 32.00 | 32.00 | 90.00 | 30.00 | 40.00 |
| Book value per share (βΉ) | 133.85 | 115.19 | 104.93 | 102.79 | 157.19 | 87.26 | 107.47 |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1,180 | 924 | 989 | 1,023 | 974 | 805 | 966 | 946 |
| Revenue growth (YoY) | +21.2% | +14.9% | +2.4% | +8.1% | -2.6% | -0.8% | - | - |
| Other income | 72.77 | 61.63 | 35.71 | 31.82 | 33.91 | 43.76 | 39.46 | 35.06 |
| Total expenses | 780 | 631 | 642 | 655 | 639 | 554 | 635 | 656 |
| EBITDA | 400 | 293 | 347 | 368 | 335 | 251 | 331 | 290 |
| EBITDA margin | +33.9% | +31.7% | +35.1% | +35.9% | +34.4% | +31.2% | +34.2% | +30.7% |
| Depreciation | 15.02 | 15.84 | 13.17 | 20.32 | 17.43 | 15.52 | 14.72 | 18.80 |
| Interest | 0.49 | 0.97 | 0.61 | 1.19 | 0.51 | 0.42 | 0.58 | 0.09 |
| Profit before tax | 458 | 338 | 369 | 378 | 351 | 279 | 355 | 306 |
| Tax | 123 | 84.65 | 94.18 | 101 | 95.65 | 73.87 | 94.76 | 77.77 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 3,790 | 3,723 | 3,407 | 3,216 | 3,218 | 2,920 | 3,225 |
| Revenue growth | +1.8% | +9.3% | +5.9% | -0.0% | +10.2% | -9.4% | - |
| Other income | 145 | 147 | 143 | 115 | 1,423 | 218 | 624 |
| Total expenses | 2,490 | 2,554 | 2,670 | 2,428 | 2,483 | 2,532 | 3,438 |
| Employee cost | 607 | 580 | 624 | 595 | 610 | 616 | 629 |
| EBITDA | 1,300 | 1,169 | 737 | 788 | 734 | 389 | (213) |
| EBITDA margin | +34.3% | +31.4% | +21.6% | +24.5% | +22.8% | +13.3% | -6.6% |
| Depreciation | 66.44 | 66.79 | 69.68 | 65.77 | 68.19 | 78.60 | 82.68 |
| Interest | 2.73 | 1.31 | 1.80 | 1.81 | 1.99 | 3.53 | 6.34 |
| Profit before tax | 1,376 | 1,248 | 809 | 835 | 2,087 | 524 | 322 |
| Tax | 364 | 329 | 224 | 228 | 397 | 167 | 212 |
| Net profit | 908 | 827 | 651 | 587 | 1,679 | 475 | 197 |
| Net profit margin | +24.0% | +22.2% | +19.1% | +18.2% | +52.2% | +16.3% | +6.1% |
| EPS (βΉ) | 59.73 | 54.25 | 34.51 | 35.88 | 99.79 | 21.11 | 6.50 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 169 | 169 | 169 | 169 | 169 | 169 | 169 |
| Reserves & surplus | 2,072 | 1,780 | 1,615 | 1,584 | 2,508 | 1,328 | 1,671 |
| Shareholders' funds (net worth) | 2,241 | 1,949 | 1,784 | 1,753 | 2,678 | 1,497 | 1,840 |
| Secured loans | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Unsecured loans | 33.27 | 9.95 | 18.67 | 15.54 | 20.08 | 34.63 | 0.18 |
| Total debt | 33.27 | 9.95 | 18.67 | 15.54 | 20.08 | 34.63 | 0.18 |
| Total liabilities | 2,534 | 2,208 | 2,049 | 2,023 | 2,961 | 1,792 | 2,130 |
| Assets | |||||||
| Gross block | 700 | 669 | 683 | 636 | 594 | 603 | 1,455 |
| Net block | 281 | 284 | 321 | 330 | 331 | 387 | 758 |
| Capital work in progress | 32.93 | 14.32 | 13.93 | 20.31 | 30.50 | 13.21 | 120 |
| Investments | 1,416 | 1,143 | 838 | 543 | 390 | 24.49 | 24.49 |
| Inventories | 430 | 463 | 514 | 438 | 513 | 523 | 483 |
| Sundry debtors | 273 | 293 | 222 | 192 | 205 | 216 | 99.80 |
| Cash & bank balances | 1,355 | 1,401 | 1,061 | 1,151 | 2,479 | 1,158 | 1,066 |
| Loans & advances | 93.90 | 109 | 155 | 168 | 108 | 275 | 108 |
| Total current assets | 2,152 | 2,265 | 1,953 | 1,948 | 3,305 | 2,171 | 1,757 |
| Total current liabilities | 1,741 | 1,893 | 1,499 | 1,305 | 1,662 | 1,305 | 1,002 |
| Net working capital | 411 | 372 | 454 | 644 | 1,643 | 866 | 755 |
| Total assets | 2,534 | 2,208 | 2,049 | 2,023 | 2,961 | 1,792 | 2,130 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 536 | 62.15 | 29.74 | 281 | 405 | 98.03 | 97.78 |
| Net cash from operating activities | 881 | 1,280 | 579 | 488 | 820 | 595 | 491 |
| Net cash from investing activities | 385 | (36.53) | 14.97 | 805 | (420) | 408 | (63.10) |
| Net cash from financing activities | (737) | (769) | (562) | (1,544) | (524) | (696) | (428) |
| Net change in cash | 530 | 474 | 32.41 | (251) | (124) | 307 | 0.25 |
| Closing cash | 1,355 | 1,401 | 1,061 | 1,151 | 2,479 | 1,158 | 1,066 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +1.8% | +9.3% | +5.9% | -0.0% | +10.2% | -9.4% | - |
| EBITDA growth | +11.2% | +58.6% | -6.4% | +7.3% | +89.0% | +282.5% | - |
| PBT growth | +10.2% | +54.3% | -3.2% | -60.0% | +298.3% | +62.5% | -51.4% |
| Net income growth | +9.8% | +27.0% | +11.0% | -65.1% | +253.3% | +141.1% | - |
| Revenue CAGR (3Y) | +5.6% | +5.0% | +5.3% | -0.1% | +0.9% | +0.6% | +3.6% |
| EBITDA CAGR (3Y) | +18.2% | +16.8% | +23.8% | - | +9.2% | -8.6% | - |
| Profitability & leverage | |||||||
| Net income margin | +26.7% | +24.7% | +17.2% | +18.9% | +52.5% | +12.2% | +3.4% |
| Return on capital employed | +58.2% | +58.7% | +44.4% | +33.6% | +32.1% | +32.1% | +28.4% |
| Return on net worth | +48.3% | +49.2% | +36.8% | +27.4% | +80.5% | +28.5% | +9.9% |
| Debt / equity | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 |
| Long-term debt / equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.00 |
| Interest cover | 0.22 | 0.12 | 0.27 | 0.25 | 0.30 | 1.14 | -2.15 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 5.54 | 5.51 | 5.17 | 5.23 | 5.38 | 2.84 | 3.20 |
| Inventory turnover | 8.48 | 7.62 | 7.16 | 6.77 | 6.21 | 5.80 | 6.65 |
| Debtors turnover | 13.40 | 14.47 | 16.44 | 16.18 | 15.29 | 18.52 | 29.28 |
| EPS (βΉ) | 59.73 | 54.25 | 34.51 | 35.88 | 99.79 | 21.11 | 6.50 |
| Dividend per share (βΉ) | 57.00 | 54.00 | 32.00 | 32.00 | 90.00 | 30.00 | 40.00 |
| Book value per share (βΉ) | 132.30 | 115.06 | 105.31 | 103.48 | 158.06 | 88.37 | 108.62 |
Investments & Acquisitions by GSK
GSK has strategically engaged in corporate development activities, having acquired 23 companies. Notable acquisitions include 35Pharma, Affinivax and Aiolos Bio.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Therapeutic solutions for cancer, including NSCLC inhibitors, are developed. | nuvalent.com | Cambridge, United States | 2017 | Jun 2026 | $10.6B | |
Designs and develops innovative biologics for unmet medical needs in healthcare. | 35pharma.com | Montreal, Canada | 2021 | Feb 2026 | $950M | |
Developer of RNA therapeutics to treat undruggable diseases | elsiebio.com | San Diego, United States | 2021 | Jun 2024 | $50M | |
Biotech company focused on developing innovative therapies for respiratory diseases and immune conditions | aiolosbio.com | Boston, United States | 2023 | Jan 2024 | β’β’β’β’ | |
GSK is engaged in developing biopharmaceutical solutions globally. | bellushealth.com | Laval, Canada | 1993 | Apr 2023 | $2B | |
Aircraft engines and traditional propulsion systems are manufactured. | solutionf.com | Venelles, France | 1985 | Jul 2022 | β’β’β’β’ | |
Technology-based conjugate vaccines against infectious diseases are developed. | affinivax.com | Cambridge, United States | 2013 | May 2022 | $2.1B | |
Oncology therapeutics for cancer treatment and nausea prevention are developed. | tesarobio.com | Waltham, United States | 2010 | Dec 2018 | $5.1B | |
Developer of vaccines against a range of infectious diseases | okairos.com | Basel, Switzerland | 2007 | β’β’β’β’ | ||
Bioconjugate vaccines for bacterial infections are developed using proprietary technology. | glycovaxyn.com | Schlieren, Switzerland | 2004 | β’β’β’β’ |
Complete acquisition details for GSK
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of GSK
14 dated milestones of GSK across 23 years, from founding to its latest funding, stage changes and deals.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $394K.
- Acquisition Acquires TESARO.
- Exit Acquired by Unilever.
- Acquisition Acquires GSK.
- Acquisition Acquires Affinivax.
- Acquisition Acquires Solution F.
- Acquisition Acquires GSK.
- Funding Latest funding round, Grant, of $415K.
- Acquisition Acquires Aiolos Bio.
- Acquisition Acquires Elsie Biotechnologies.
- Acquisition Acquires GSK.
- Acquisition Acquires 35Pharma.
- Acquisition Acquires Nuvalent.
Web traffic of GSK
The website of GSK (gsk.com) receives about 1.3M visits a month and ranks #56,834 among all websites worldwide, #1,503 in Health.
- Monthly visits1.3M
▲ 54.6% vs previous month
- Unique visitors374.3K
per month
- Global rank#56,834
among all websites
- Category rank#1,503
Health · Health
- Bounce rate43%
- Pages per visit3.6
- Average visit2 min 25 sec
- DevicesDesktop 52% Β· Mobile 48%
Websites whose visitors overlap most with GSK. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| abbott.com | 100% | 917.2K | #65,577 | View details | |
| bms.com | 98% | 809.8K | #67,210 | View details | |
| lilly.com | 98% | 4.9M | #13,252 | View details | |
| novartis.com | 94% | 948.8K | #58,822 | View details | |
| boehringer-ingelheim.com | 93% | 1.6M | #39,825 | View details | |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
All 40 similar websites and full traffic analytics for GSK
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 40 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Gsk
Complete news archive for GSK
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about GSK
GSK was founded in 1715 and raised its 1st funding round 293 years after it was founded.
GSK is headquartered in Brentford, United Kingdom. It is registered at Brentford, England, United Kingdom.
Dame Emma Walmsley is the CEO of GSK, as recorded in our data.
GSK has 91,864 employees.
The primary company behind GSK, Glaxosmithkline Pharmaceuticals Limited, reported revenue of βΉ3,988 Cr for FY 2026, up 2% year on year.
Founded in 1715, GSK operates in the pharmaceutical sector, with a focus on research, development, clinical trials, and commercialization of medicines and vaccines. Treatments are provided for respiratory, immunology, inflammatory, oncology, HIV, and infectious diseases. Global access to products is emphasized, alongside sustainable practices, from its base in Brentford, United Kingdom.
Yes, GSK is publicly traded on LSE under the ticker symbol GSK.
GSK has made 23 acquisitions, including 35Pharma, Affinivax, and Aiolos Bio.
GSK has 10 investors. Key investors include Unilever, Elliott Management, Scottish Enterprise, CARB-X, and European Union.
GSK operates through Glaxosmithkline Pharmaceuticals Limited.
Yes. GSK was acquired by Unilever in December 2018.
The legal entities of GSK currently have 9 directors, including Subesh Ronald Williams, Renu Sud Karnad, Sunita Maheshwari and others.

